GlaxoSmithKline Makes Generics Deal to Penetrate Emerging Markets

July 23, 2008 -- GlaxoSmithKline (NYSE: GSK) has made a strategic alliance with Aspen PharmaCare, a South African generic drug company, as a means of penetrating emerging markets such as China. GSK noted that 40% of the expected growth in pharmaceutical markets worldwide will be in emerging countries. GSK did not pay an upfront fee in its arrangement with Aspen, but will make a small upfront payment for each product that it elects to register and then pay royalties, as the big pharma extends the marketing range of Aspen’s products into new territories. More details...
MORE ON THIS TOPIC